Drugs / DS-1205c
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03255083 | Apr 2019 → Sep 2020 | non-small cell lung carcinoma | Daiichi Sankyo | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03599518 | Sep 2018 → Apr 2020 | non-small cell lung carcinoma | Daiichi Sankyo | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-1205c | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03255083 ↗ |
| Action | Inhibit | “an oral AXL-receptor inhibitor” PMID 36892745 ↗ Mar 2023 |
| Modality | Small molecule | “DS-1205c is a novel, specific, orally bioavailable, small-molecule AXL receptor TKI.” PMID 36621830 ↗ Jan 2023 |
| Route | Oral | “Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 800 mg, 1200 mg)” NCT03255083 ↗ |
| Target | AXL | “an AXL kinase inhibitor” PMID 36892745 ↗ Mar 2023 |